Approach to peri-CAR T-cell risk stratification with monitoring and treatment options. This figure highlights various preinfusion risk factors that may affect long-term EFS, remission durability, and/or OS; and how these factors are further modulated by post–CAR T-cell outcomes, based primarily on NGS-MRD status and loss of BCA. Refer to Table 1 for specific information on risk factors. ASAP, as soon as possible; Blina, blinatumomab; CRi, complete remission with incomplete count recovery.